Turn Therapeutics Inc. (TTRX) 股票分析

公司概述

Turn Therapeutics Inc. (TTRX) operates as a specialized pharmaceuticals company dedicated to developing therapeutic agents for dermatological conditions, specifically targeting diseases affecting the skin, nails, and eyes. This business model positions the firm within the Healthcare sector and the Biotechnology industry, where value is derived from research and development rather than immediate commercial scale. The company currently maintains a market capitalization of $104.26M, while its annual revenue and employee count are not publicly disclosed in the available financial data. The valuation metrics indicate a small-cap biotechnology entity that is likely in a critical pre-commercial or early commercialization phase, relying heavily on capital deployment for product development rather than generating substantial operational revenue streams.

财务健康

The company reported a net loss of $-3,194,080 over the trailing twelve months, accompanied by an EBITDA of $-6,302,850, which highlights a significant divergence between top-line revenue and bottom-line profitability typical of the biotech sector. Although specific revenue figures are unavailable, the substantial negative net income relative to EBITDA suggests a cost structure where operating expenses, likely driven by R&D and administrative costs, are consuming cash flow before reaching the net income line. Notably, Turn Therapeutics generated positive free cash flow of $1.74M, providing a degree of financial flexibility that allows the company to fund operations without immediate external financing despite its net loss position. The balance sheet reflects a cash reserve of $5.08M against total debt obligations of $80,376, resulting in a debt-to-equity ratio of 1.72. While the positive free cash flow offers liquidity, the debt-to-equity ratio of 1.72 indicates a leveraged capital structure where equity claims are less than twice the debt burden, requiring careful monitoring of cash burn rates. The current ratio stands at 0.87, signaling that short-term liquid assets are insufficient to cover short-term liabilities without additional capital injection or asset liquidation. Furthermore, the return on equity is reported at -141.7% and the return on assets is -55.9%, metrics that reveal management is currently generating negative returns on the capital base, a common characteristic of companies investing heavily in future growth rather than current profitability.

估值评估

The trailing twelve-month P/E ratio is listed as N/A due to the lack of earnings, while the forward P/E is calculated at -23.33, a figure that implies market expectations of future earnings recovery but currently reflects the negative earnings trajectory of the stock. The price-to-book ratio is exceptionally high at 194.44, indicating that the market prices the company's equity at a massive premium over its tangible book value, a valuation typical for asset-light biotech firms where intangible value and pipeline potential outweigh current book assets. Alternative valuation metrics such as price-to-sales are N/A given the lack of revenue data, and the EV/EBITDA stands at -15.75, suggesting that traditional valuation multiples are not applicable without positive earnings or sales. The stock has exhibited significant volatility, trading within a 52-week range between a low of $2.57 and a high of $26.50. Without a specific current price provided in the facts, the position relative to the 52-week high cannot be mathematically calculated, but the range itself underscores the speculative nature of the asset. The beta is listed as N/A, meaning volatility relative to the broader market is not quantifiable with the provided data, yet the wide spread between the 52-week high and low suggests inherent price instability common in small-cap biotechnology stocks.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue within the historical context provided. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that Turn Therapeutics reinvests all available resources and cash flow back into research and development activities rather than distributing income to shareholders. The absence of a dividend policy is consistent with the company's lifecycle stage, where capital preservation and growth investment take precedence over income distribution to investors. Overall, the financial profile presents a high-risk, high-reward scenario characterized by negative profitability metrics, a leveraged balance sheet relative to equity, and a lack of dividend income, relying entirely on the potential future commercialization of its skin and eye disease therapies to drive valuation expansion.